Warfarin and bosentan interaction in a patient with pulmonary hypertension secondary to bilateral pulmonary emboli

Clinical Therapeutics

Volumn 32, Issue 1, 2010, Pages 53-56

  Spangler, Mikayla L ^a   Saxena, Shailendra ^b  

^a CREIGHTON UNIVERSITY SCHOOL OF PHARMACY AND HEALTH PROFESSIONS   (United States)

^b CREIGHTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

bosentan; drug interaction; international normalized ratio; warfarin

Indexed keywords

ANTICOAGULANT AGENT; ANTIHYPERTENSIVE AGENT; BOSENTAN; CYP2C9 PROTEIN, HUMAN; CYP3A4 PROTEIN, HUMAN; CYTOCHROME P450 3A; SULFONAMIDE; UNSPECIFIC MONOOXYGENASE; WARFARIN;

ARTICLE; CASE REPORT; DOSE RESPONSE; DRUG ADMINISTRATION; DRUG EFFECT; DRUG INTERACTION; FEMALE; HUMAN; INTERNATIONAL NORMALIZED RATIO; LUNG EMBOLISM; METABOLISM; MIDDLE AGED; PULMONARY HYPERTENSION; TREATMENT OUTCOME;

ANTICOAGULANTS; ANTIHYPERTENSIVE AGENTS; ARYL HYDROCARBON HYDROXYLASES; CYTOCHROME P-450 CYP3A; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG INTERACTIONS; FEMALE; HUMANS; HYPERTENSION, PULMONARY; INTERNATIONAL NORMALIZED RATIO; MIDDLE AGED; PULMONARY EMBOLISM; SULFONAMIDES; TREATMENT OUTCOME; WARFARIN;

MLCS; MLOWN;

EID: 77952297026     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2010.01.004     Document Type: Article

References (14)

1. Jamieson, SW, Kapelanski, DP, Pulmonary endarterectomy. Curr Probl Surg. 37 (2000), 165–252.
2. Pengo, V, Lensing, AW, Prins, MH, et al., Thromboembolic Pulmonary Hypertension Study Group. Incidence of chronic thromboembolic pulmonary hypertension after pulmonary embolism. N Engl J Med. 350 (2004), 2257–2264.
3. Ulrich, S, Speich, R, Domenighetti, G, et al. Bosentan therapy for chronic thromboembolic pulmonary hypertension. A national open label study assessing the effect of bosentan on haemodynamics, exercise capacity, quality of life, safety and tolerability in patients with chronic thromboembolic pulmonary hypertension (BOCTEPH-Study). Swiss Med Wkly. 137 (2007), 573–580.
4. Kim, NH, Assessment of operability in chronic thromboembolic pulmonary hypertension. Proc Am Thorac Soc. 3 (2006), 584–588.
5. Tracleer (bosentan) [product information]. Inc South San Francisco, Calif: Actelion Pharmaceuticals US, Inc. 2009 http://www.tracleer.com/pdf/TracleerFullPI_Aug2009.pdf Accessed January 4, 2010.
6. Coumadin (warfarin sodium) [product information]. Princeton, NJ: Bristol-Myers Squibb Pharmaceutical Company; 2009 http://packageinserts.bms.com/pi/pi_coumadin.pdf Accessed January 4, 2010.
7. Weber, C, Banken, L, Birnboeck, H, Schulz, R, Effect of the endothelin-receptor antagonist bosentan on the pharmacokinetics and pharmacodynamics of warfarin. J Clin Pharmacol 39 (1999), 847–854.
8. Nauser, TD, Stites, SW, Diagnosis and treatment of pulmonary hypertension. Am Fam Physician 63 (2001), 1789–1798.
9. Horn, JR, Hansten, PD, Chan, LN, Proposal for a new tool to evaluate drug interaction cases. Ann Pharmacother 41 (2007), 674–680.
10. Hoeper, MM, Kramm, T, Wilkens, H, et al. Bosentan therapy for inoperable chronic thromboembolic pulmonary hypertension. Chest. 128 (2005), 2363–2367.
11. Ansell, J, Hirsh, J, Hylek, E, et al. Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest. 133:Suppl 6 (2008), 160S–198S.
12. Murphey, LM, Hood, EH, Bosentan and warfarin interaction. Ann Pharmacother 37 (2003), 1028–1031.
13. Dingemanse, J, van Giersbergen, PL, Clinical pharmacology of bosentan, a dual endothelin receptor antagonist. Clin Pharmacokinet 43 (2004), 1089–1115.
14. Rubin, LJ, Badesch, DB, Barst, RJ, et al. Bosentan therapy for pulmonary arterial hypertension [published correction appears in N Engl J Med. 2002;346:1258]. N Engl J Med. 346 (2002), 896–903.